Leap's most advanced clinical candidate, sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is currently being developed for the treatment of esophagogastric cancer, gynecological tumors, and colorectal cancer patients. FL-301 is a humanized monoclonal antibody targeting Claudin18.2, currently being developed for the treatment of gastric and pancreatic cancer patients. Leap also has a humanized monoclonal antibody named FL-501, which targets growth differentiation factor 15 (GDF-15) protein and is currently in the preclinical development stage.

Leap's most advanced clinical candidate, sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is currently being developed for the treatment of esophagogastric cancer, gynecological tumors, and colorectal cancer patients. FL-301 is a humanized monoclonal antibody targeting Claudin18.2, currently being developed for the treatment of gastric and pancreatic cancer patients. Leap also has a humanized monoclonal antibody named FL-501, which targets growth differentiation factor 15 (GDF-15) protein and is currently in the preclinical development stage.

Leap's most advanced clinical candidate, sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is currently being developed for the treatment of esophagogastric cancer, gynecological tumors, and colorectal cancer patients. FL-301 is a humanized monoclonal antibody targeting Claudin18.2, currently being developed for the treatment of gastric and pancreatic cancer patients. Leap also has a humanized monoclonal antibody named FL-501, which targets growth differentiation factor 15 (GDF-15) protein and is currently in the preclinical development stage.